AMEX · Biotechnology

Theriva Biologics, Inc. (TOVX) Stock

$0.22 -4.45% AMEX: TOVX Healthcare

Valuation

MetricValue
Price$0.22
Market Cap$9.96M
P/E Ratio-0.34
P/B Ratio0.85
P/S Ratio34.43
EPS (TTM)$-2.08
52-Week High$0.86
52-Week Low$0.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-93.49%
ROA-33.33%
ROCE-52.31%
Gross Margin92.00%
Operating Margin-72.45%
Net Margin-71.53%
Debt/Equity0.29
Current Ratio1.70

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-22.0M$-21.0M$-26.0M$-15.0M
Net Profit$-14.0M$-20.0M$-18.0M$-26.0M$-25.0M
EPS$-1.90$-32.66$-28.48$-19.03$-2.08
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$70.0M$72.0M$55.0M$35.0M$38.0M
Total Liabilities$5.0M$17.0M$16.0M$16.0M$23.0M
Cash$67.0M$42.0M$23.0M$12.0M$13.0M
Borrowings$2.0M$2.0M$2.0M$2.0M$3.0M

Latest News

Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy MT Newswires · Jul 7, 2026 Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma GlobeNewswire · Jul 7, 2026 Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research GlobeNewswire · Jun 11, 2026 Theriva Biologics: Q1 Earnings Snapshot Associated Press · May 5, 2026 Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results GlobeNewswire · May 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-19.0M$-19.0M$-17.0M$-17.0M
Investing Cash Flow$0$-5.0M$0$0$0
Financing Cash Flow$8.0M$-3.0M$-2.0M$0$3.0M
Net Cash Flow$61.0M$-25.0M$-19.0M$-12.0M$1.0M
Free Cash Flow$-13.0M$-19.0M$-19.0M$-17.0M$-17.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.22
FCF Yield-119.79%
Quick Ratio1.13
Interest Coverage0.00
Return 1Y-48.32%
Return 3Y-98.61%
Return 5Y-99.81%

Ownership

Insiders Held1.63%
Institutions Held4.32%
Institutions Float Held4.39%
Institutional HolderSharesReport Date
Geode Capital Management, LLC450,2632026-03-31
Virtu Financial LLC253,2182026-03-31
Vanguard Fiduciary Trust Co241,7802026-03-31
UBS Group AG225,6242026-03-31
Vanguard Capital Management LLC192,4042026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCTXZBriaCell Therapeutics Corp. Warrant $0.10 +8.47% -0.30 $188186 0.00%
BIVIBioVie Inc. $1.39 +8.59% -0.46 $10.48M 0.00%
CARMCarisma Therapeutics, Inc. $0.01 -5.17% 0.01 $230148 0.00%
CMMBChemomab Therapeutics Ltd. $1.43 -2.72% -1.30 $8.80M 0.00%
ELABPMGC Holdings Inc. $3.08 -1.60% 0.00 $1.40M 0.00%

About Theriva Biologics, Inc.

Theriva Biologics, Inc. is led by CEO Steven A. Shallcross, employs 20 people, headquartered in US, publicly traded since 2006.

Theriva Biologics, Inc. (TOVX) stock trades at $0.22 with a market capitalization of $9.96M. The stock is valued at a price-to-earnings (P/E) ratio of -0.34, price-to-book of 0.85, price-to-sales of 34.43. Over the past 52 weeks the stock has ranged between $0.16 and $0.86, and currently trades 74.5% below its 52-week high.

On profitability, Theriva Biologics, Inc. generates a return on equity (ROE) of -93.49%, return on capital employed of -52.31%, an operating margin of -72.45%, a net profit margin of -71.53%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides